Trial
NCT02320292
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
—
Condition
Ann Arbor Stage I Grade 1 Follicular Lymphoma
Intervention
Quality-of-Life Assessment
Why stopped
drug supply issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-09